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ABSTRACT
Objective: This study involves preparation and evaluation of floating tablets of ritonavir (RN) for improving the drug bioavailability by prolongation 
of gastric residence time. RN is an antiretroviral agent used in the treatment of HIV and viral diseases have been taken as a model drug in this 
investigation because of its low biological half-life (3-5 hrs). Moreover, it is primarily absorbed from stomach.
Methods: RN floating tablets were prepared by the dry granulation technique, using guar gum and xanthan gum as polymers, sodium bicarbonate as 
effervescent agent, polyvinylpyrrolidone as binding agent, Dicalcium phosphate as diluents, crospovidone as swelling agent and magnesium stearate 
as lubricant. The prepared tablets were evaluated for various physicochemical parameters.
Results: Drug-excipient interaction studies were conducted by Fourier transform infrared spectroscopy and differential scanning calorimetry. 
The results suggested that there was no incompatibility between the drug and polymers. The prepared tablets were evaluated for their physical 
characteristics. All the parameters were within the pharmacopoeial limits. Further, tablets were also studied for their floating properties and in vitro 
drug release characteristics. The tablets exhibited controlled and prolonged drug release profiles. The developed formulation was found to be stable.
Conclusion: The developed floating tablets of RN exhibit prolonged release up to 12 hrs, and thus may improve bioavailability and minimize 
fluctuations in plasma drug concentrations.
Keywords: Ritonavir, Floating tablets, Gastric residence time, Gastroretentive drug delivery system.
INTRODUCTION
For the last three decades, oral controlled release dosage forms have 
been developed due to their important therapeutic advantages. 
By the introduction of a variety of controlled delivery systems, the 
inconvenience of conventional tablets or capsules was overcome. This 
controlled release technology had made it possible to release drugs at 
a constant release rate for longer periods of time. However, this benefit 
had not satisfied a variety of important drugs that (i) are locally active 
in the stomach, (ii) have an absorption window in the stomach or in 
the upper small intestine, (iii) are unstable in the intestinal or colonic 
environment, or (iv) exhibit low solubilities at high pH values [1-3]. 
These limits promoted the development of gastroretentive drug 
delivery systems (GRDDS). GRDDS are the systems which are retained 
in the stomach for a longer period of time and thereby improve the 
bioavailability of drugs that are preferentially absorbed from the upper 
gastrointestinal tract.
Various approaches have been proposed to achieve gastric retention 
and includes co-administration of drugs or pharmaceutical excipients 
that influence the gastric motility pattern and thereby delay gastric 
emptying [4], magnetic systems [5], mucoadhesive systems [6], swelling 
or unfolding [7], density-controlled systems that either float on gastric 
contents [8] or sediment and combination systems [9].
Ritonavir (RN) is a protease inhibitor widely prescribed in antiretroviral 
regimen. It blocks the HIV protease, thereby reducing the viral load 
in the infected individual [10]. This drug is mainly suffers with low 
oral bioavailability due to degradation of RN by the cytochrome 
P450-3A4 (CYP3A4) isoenzymes in the distal intestine [11],  efflux of the 
absorbed drug by counter transporter proteins (mainly P-glycoprotein) 
present in the distal intestine [12,13] and is unstable at alkaline 
pH [14]. It shows pH-dependent solubility and solution stability [15]. 
Moreover, it is primarily absorbed from stomach [16] and having short 
half-life (~3-5 hrs). Due to these characteristics, it was selected for the 
development of GRDDS.
METHODS
RN was obtained as a gift sample from Novartis, Hyderabad. Guar gum, 
xanthan gum was purchased from Colorcon Asia Private Limited, India. 
Sodium bicarbonate, crospovidone, Dicalcium phosphate, magnesium 
stearate, and polyvinylpyrrolidone (PVP) k-30 were purchased from 
S. D. Fine-Chem. Ltd., Mumbai, India.
Procedure for preparation of RN floating tablets
Accurately weighed quantities (Table 1) of polymer and Dicalcium 
phosphate, crospovidone were taken in a mortar and mixed 
geometrically. To this required quantity of RN was added and mixed 
slightly with pestle. Accurately weighed quantity of sodium bicarbonate 
was taken separately in a mortar and powdered with pestle. The 
powder was passed through sieve No. 40 and mixed with the drug 
blend which was also passed through sieve No. 40. The whole mixture 
was collected in a plastic bag and mixed for 3 minutes. To this PVP K30 
was added and mixed for 2 minutes. The mixture equivalent to 300 mg 
was compressed into tablets with 10 mm flat punches at a hardness 
of 5 kg/cm2. The composition of the different formulations is shown in 
Table 1.
Solubility studies
The equilibrium solubility of RN was measured in 0.1 M hydrochloric 
acid (pH of 1.2), phosphate buffer of pH 6.8, and pH 7.4 to determine its 
solubility. Excess amounts of the drug were added to 50 ml-stoppered 
conical flasks (n=3). The flasks were shaken mechanically at 37°C±0.5°C 
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for 24 hrs, in a horizontal shaker (HS 501 Digital, IKA-Labortechnik, 
and Staufen, Germany). After 2 days of equilibrium, aliquots were 
withdrawn and filtered (0.22 µm pore syringe filter). Then, the filtered 
samples were diluted with an appropriate amount of dissolution 
medium and assayed by ultraviolet (UV)-spectrophotometer at 210 nm 
for RN.
Drug-excipient interaction study: Differential scanning 
calorimetry (DSC)
DSC thermo grams were recorded on a DSC (Perkin-Elmer, New York, NY). 
The instrument was calibrated with an indium standard. The samples 
(2-4 mg) were heated (20-300°C) at a constant scanning speed 
(10°C/minutes) in sealed aluminum pans, using nitrogen purged gas.
Fourier-transform infrared (FTIR) spectroscopy
Drug-polymer compatibility studies were conducted using FTIR 
spectrophotometer (Schimadzu) by KBr pellet technique. IR spectrum 
of pure drug and polymers were seen in between 4000 and 400 cm−1.
Evaluation of physicochemical properties
The prepared tablets were evaluated for parameters such as hardness, 
friability, weight variation, thickness, in vitro drug release, floating lag 
time (FLT), total buoyancy time, and stability study.
Wight variation
A total of 20 tablets were randomly selected and were weighed using an 
electronic balance (Shimadzu BL-22OH, Japan). Results are expressed 
as mean value and standard deviation (SD).
Hardness test
The hardness tests of the tablets were determined using Monsanto 
hardness tester (Campbell Electronics, India). For each formulation, the 
hardness of six tablets was determined. Hardness values are reported 
in kg/cm2. Mean and SD values were also calculated.
Thickness
The thickness of the tablets was determined by using vernier calipers 
(Mitutoyo, Japan). 10 tablets from each batch were used. Mean and SD 
values were also calculated.
Friability
About 10 tablets were weighed and subjected for this test by using 
Roche friabilator (Erection instrument and engineering, Ahmadabad, 
India).
Drug content
About 10 tablets from each batch were taken and triturated, powder 
equivalent to its average weight and were transferred into a 100 ml 
volumetric flask, to this 50 ml of 0.1N HCl was added then shaken for 
5 minutes and make the final volume with 0.1N HCl up to 100 ml. Then 
the solution was sonicated for 15 minutes and filtered, then absorbance 
was determined at 210 nm using UV/visible spectrophotometer (Elico, 
SL 159, India) against 0.1N HCl blank.
Floating behavior
The buoyancy property was determined by the FLT and total floating 
time (TFT) by placing the tablet in a 250 ml beaker containing 0.1N HCl 
and was observed visually.
In vitro dissolution studies
In vitro drug release studies were conducted for a period of 12 hrs using 
USP XXIV type-II (Paddle) dissolution apparatus (Lab India, India) at 
37±0.5oC at 50 rpm using 900 ml of 0.1N HCl as dissolution medium. 
5 ml of sample was withdrawn in predetermined time intervals from the 
dissolution medium and replaced with fresh medium to maintain the 
sink condition. Then, the samples were analyzed for RN by UV/visible 
spectrophotometer (Elico, SL 159, India) at 210 nm.
Kinetic modeling of drug release profiles
The dissolution profiles of all formulae in 0.1 N HCl were fitted to 
zero-order, first-order, Higuchi [17] and Korsmeyer–Peppas kinetic 
models [18]. The model with the highest correlation coefficient was 
considered to be the best fitting one.
Physical stability studies
Physical stability studies were conducted according to International 
Conference on Harmonization guidelines [19]. One of the optimized 
formulations was placed in a desiccator containing saturated sodium 
chloride solution (75% Rh). The desiccator was stored at 40°C for 
3 months. At predetermined time intervals, the tablets were examined 
for hardness, FLT, TFT, drug content, and drug release.
RESULTS AND DISCUSSION
RN exhibited a pH dependent solubility phenomenon in different 
buffers. It shows maximum solubility in 0.1N HCl, while the solubility 
was decreased as the pH increased.
Drug-excipients interaction study
DSC studies indicated a sharp endothermic peak at 120-125°C 
corresponding to its melting point, for pure RN (Fig. 1). No significant 
change in the position of this peak or broadening of peak in the 
thermogram of drug and excipient mixture was observed with respect 
to the thermogram of pure drug (Fig. 2). Hence, it can be concluded that 
the drug and excipients do not interact with each other.
Drug-polymer interactions were studied by fourier transform-infrared 
spectroscopy analysis. Fig. 3 showed the IR spectra of pure RN. The 
characteristic CH stretching, NH stretching of secondary amine, 
C=C stretching, and C=O stretching of pure drug was observed at 
2964.47 cm−1, 3357.73 cm−1, 3025.35 cm−1, and 1714.67 cm−1. The 
characteristic peaks confirmed the structure of RN. The same peaks 
were also reported in the physical mixture (Fig. 4). Hence, it indicates 
the stable nature of drug in all formulations.
Physical properties of tablets
The tablets of RN were prepared by direct compression method using 
natural polymers (xanthan gum, guar gum). The data of physical parameters 
Table 1: Composition of the ritonavir floating tablets
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
Ritonavir 100 100 100 100 100 100 100 100 100 100
Guar gum 20 40 60 80 100 - - - - -
Xanthan gum - - - - - 20 40 60 80 100
NaHCO3 40 40 40 40 40 40 40 40 40 40
DCP 90 70 50 30 10 90 70 50 30 10
Crospovidone 30 30 30 30 30 30 30 30 30 30
Magnesium stearate 5 5 5 5 5 5 5 5 5 5
PVP K-30 15 15 15 15 15 15 15 15 15 15
Total tablet weight 300 300 300 300 300 300 300 300 300 300
DCP: Di calcium phosphate, PVP: Polyvinylpyrrolidone
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were presented in Table 2. All the tablet formulations showed acceptable 
physicochemical properties and complied with the pharmacopoeial 
specifications for weight variation, drug content and friability [20]. The 
physical evaluation of the tablets revealed uniform thickness and weight 
for all the tablets (evident from low SD values). The hardness values 
between 5 and 5.3 kg/cm2 and low friability values (below 0.45%) across 
all formulations indicated that the tablets had sufficient mechanical 
strength. The drug content uniformity studies revealed that drug content 
between 96.33±2.3% and 98.91±2.8% is acceptable.
FLT and TFT
In this study, sodium bicarbonate was used as a gas-generating agent 
to aid floating of tablets. The in vitro testing revealed the ability of 
most formulations to maintain buoyant for more than 12 hrs (Table 2 
and Fig. 5). As shown in Table 2, all the formulations floated with a lag 
time of < 1 minute. The FLT of the formulations F1-F5 prepared with 
different concentrations of guar gum with constant sodium bicarbonate 
ratio, ranged from 15 to 35 seconds and that of formulations F6-F10, 
prepared with xanthan gum, ranged from 37 to 62 seconds had no 
significant effect. In all the formulations, as the concentration of sodium 
bicarbonate increased, the FLT was decreased [21] and TFT increased, 
but the difference in FLT was not statistically significant.
In vitro release studies
In vitro dissolution studies of all the formulations of RN tablets were 
conducted in 0.1 N HCl (pH 1.2). Formulations (F1-F5) were prepared 
Fig. 1: Differential scanning calorimetry spectra for pure drug
Fig. 2: Differential scanning calorimetry spectra for drug+excipients
Fig. 3: Fourier-transform infrared spectra for pure drug
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with varying concentrations of guar gum, and F6-F10 were prepared 
with varying concentrations of xanthan gum. The drug release profiles 
of the formulations, F1-F5 prepared with guar gum shown in Fig. 6. The 
effect of guar gum concentration on drug release was evaluated. As the 
concentration of guar gum was increased, the drug release from the 
floating tablets was significantly decreased [22]. The differences in the 
release might be due to the amount of gel layer formed on the surface of 
the tablets. If the polymer concentration is too low, a complete gel layer 
may not form resulting in a significant amount of drug being released 
too quickly or tablet may disintegrate [23].
The in vitro drug release studies revealed that formulations F1, F2, and F3 
showed a release of 92.4, 95.2, and 96.7%, respectively, in 6, 8, and 10 hrs 
(Fig. 7). Formulation F4 showed maximum drug release of 98.5% in 12 hrs. 
The variation in drug release was due to different polymer concentrations in 
all the formulations. Formulations (F1-F3) were unable to sustain the drug 
release desired period of time. Formulation F4 met the needed theoretical 
drug release profile and floated with a lag time of 18 seconds. Formulation 
F5 failed to release the required drug profile. For these reasons, F4 was 
considered as the best formulation among all the five formulations of this 
series. The results were shown in Fig. 6. Drug release profiles of formulations 
F6-F10, composed of xanthan gum, are shown in Fig. 6.
The percentage of drug released from formulations F6, F7, and F8 was 
86.8, 84.3, and 87.3, respectively, in 6, 8, and 10 hrs. This variation 
was considered to be due to different polymer concentrations in 
formulations. Further, these three formulations failed to meet the 
required theoretical drug release profile. Formulation F9 met the 
needed theoretical drug release profile and floated with a lag time 
of 37 seconds. Formulation F10 failed to release the required drug 
profile. For these reasons, F9 was considered as the best formulation 
among all the five formulations of this series. The results were shown 
in (Fig. 6). Data of the in vitro release of the optimized formulation 
were fit into different kinetic models to explain the release kinetics 
of RN from the floating tablets. The kinetic models used were a 
zero-order equation, first-order equation, Higuchi and Korsmeyer–
Peppas models (Table 3). Optimized formulation follows Higuchi 





Thickness (mm) Friability (%) Drug 
content (%)
FLT (seconds) TFT (hrs) Drug 
release (%)
F1 302 5.1±0.115 3.5±0.05 0.22 98.28 15±1 >12 99.56
F2 300 5.3±0.2 3.5±0.08 0.36 99.52 23±3 >12 97.95
F3 297 5.2±0.305 3.5±0.05 0.25 99.04 27±5 >12 80.05
F4 301 5.0±0.230 3.5±0.08 0.33 99.56 18±4 >12 99.96
F5 299 5.1±0.115 3.5±0.05 0.26 99.41 35±2 >12 97.98
F6 296 5.0±0.23 3.5±0.05 0.37 99.84 45±7 >12 89.20
F7 298 5.0±0.101 3.5±0.01 0.12 98.28 47±8 >12 70.98
F8 300 5.1±0.2 3.5±0.03 0.14 99.52 62±2 >12 66.65
F9 301 5.3±0.215 3.5±0.04 0.19 99.04 37±4 >12 98.32
F10 302 5.20±0.23 3.5±0.08 0.28 98.56 49±9 >12 84.19
FLT: Floating lag time, TFT: Total floating time
Fig. 4: Fourier-transform infrared spectra for pure drug+physical mixture
Fig. 5: Floating characteristics of ritonavir floating tablet
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model compared to all other models. Optimized formulation (F4) 
was selected for stability study based on physical characters and 
in vitro drug release. The stability study was conducted for 3 months. 
No significant change was observed in the tablet hardness, FLT, TFT, 
and drug content or in vitro dissolution (Table 4). Hence that, it can 
be concluded that the formulation F4 was stable for 3 months under 
different storage conditions
CONCLUSION
RN floating tablets were successfully formulated by floating technique. 
The optimized formulation (F4) was selected on the basis of in vitro 
buoyancy and in vitro drug release. The addition of gel forming agent 
and gas generating agent was essential to achieve in vitro buoyancy. 
The results of the in vitro drug release and in vitro buoyancy study 
showed that the optimized formulation (F4) sustained the drug 
release (98.47±0.71%) up to 12 hrs and remained buoyant for >12 hrs. 
Optimized formulation (F4) does not show any significant change in 
physical appearance, floating properties and drug release after storage 
at 40°C/75% RH and stable for 3 months.
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Fig. 6: Drug release profiles of ritonavir floating tablets composed 
of xanthan gum
Fig. 7: Drug release profiles of ritonavir floating tablets composed 
of guar gum
Table 3: The correlation coefficient (R2) values for optimized 
formulation
Zero-order First-order Higuchi Peppas
0.9815 0.7027 0.9953 0.8928
Table 4: Stability studies optimized batch
Parameters Storage conditions
At 2-8°C Room 
temperature
At 40°C
% cumulative drug release 95.10 96.82 94.73
Drug content uniformity (%) 99.13 99.35 98.46
Color change No No No
